Deployment

Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary include because glucose is in the biometric definition and Stelo pairs an FDA-cleared sensor with a genuine generative-AI insight layer rather than being a bare sensor readout. Made by DexCom (NASDAQ: DXCM) as a product line separate from its prescription G7 monitors, Stelo is the first-ever FDA-cleared over-the-counter, no-prescription continuous glucose biosensor, cleared via De Novo announced on March 5, 2024 and launched in the US on August 26, 2024 for adults 18 and older who are not on insulin, including people with type 2 diabetes not on insulin and non-diabetic users tracking the impact of diet and exercise, with a 15-day wear and no low-glucose alerts since it is not cleared for problematic hypoglycemia. Its AI augmentation is genuine: Dexcom launched a generative-AI platform for Stelo on Google Cloud's Vertex AI and Gemini, providing personalized Weekly Insights, AI photo meal logging, and up to three personalized daily recommendations drawn from glucose, activity, nutrition, and sleep, which is what tips it from a medical sensor to an in-definition biometric-AI device and fills the glucose cell distinct from the heart-rate and sleep watches and rings. Its FDA clearance makes it the strongest verification anchor of the Wave-2 set, while the marketing claim of being the first generative-AI platform in glucose biosensing is not load-bearing and is not asserted, and its exclusion of low-glucose alerting is recorded as an indication boundary.

Stelo by Dexcom · Operated by Dexcom · Catalog entry · 2 sources · not yet field-verified